[Mechanisms of action of ketamine]
- PMID: 9707750
[Mechanisms of action of ketamine]
Abstract
Racemic ketamine is a mixture of equal amounts of the two enantiomers (S)-ketamine and (R)-ketamine. The analgesic and anaesthetic potency of (S)-ketamine is about threefold superior to (R)-ketamine. Along with faster elimination, improved control of the anaesthetic state with reduced drug load is achieved. Pharmacokinetic properties of (S)-ketamine are generally comparable with the racemic mixture. The pharmacological profile of ketamine is characterized by the so-called "dissociative anaesthesic state" with profound analgesic and moderate hypnotic properties and by marked sympathomimetic reactions. Important adverse effects are hallucinations and hypersalivation. This pharmacological profile cannot be explained by a single mechanism. Analgesic, anaesthetic and sympathomimetic effects are mediated by different sites of action. N-methyl-D-aspartate (NMDA)-receptor antagonism is the most important neuropharmacological mechanism for the analgesic effects of ketamine. The same mechanism may be involved in the supposed neuroprotective potency of the substance. Effects on opiate receptors may contribute to the analgesic state as well as to dysphoric reactions. Sympathomimetic properties are mediated by enhanced central peripheral monoaminergic transmission. Inhibition of central and peripheral cholinergic transmission may contribute to the induction of anaesthetic state and hallucinations. Effects on neuromuscular transmission are unimportant. Local anaesthetic qualities are obvious as well, but are not responsible for systemic effects. At the different sites of action, qualitatively comparable effects of (S)- and (R)-ketamine were found, but significant quantitative differences are obvious as well.
Similar articles
-
[From the racemate to the eutomer: (S)-ketamine. Renaissance of a substance?].Anaesthesist. 1997 Dec;46(12):1026-42. doi: 10.1007/s001010050503. Anaesthesist. 1997. PMID: 9451486 Review. German.
-
[The clinical use of S-(+)-ketamine--a determination of its place].Anasthesiol Intensivmed Notfallmed Schmerzther. 1998 Dec;33(12):764-70. doi: 10.1055/s-2007-994851. Anasthesiol Intensivmed Notfallmed Schmerzther. 1998. PMID: 9893910 Review. German.
-
Studies with ketamine and alfentanil following Freund's complete adjuvant-induced inflammation in rats.Clin Exp Pharmacol Physiol. 2007 May-Jun;34(5-6):414-20. doi: 10.1111/j.1440-1681.2007.04581.x. Clin Exp Pharmacol Physiol. 2007. PMID: 17439409
-
Prolonged analgesic effect of ketamine, an N-methyl-D-aspartate receptor inhibitor, in patients with chronic pain.J Pharmacol Exp Ther. 1999 May;289(2):1060-6. J Pharmacol Exp Ther. 1999. PMID: 10215688 Clinical Trial.
-
Ketamine.Handb Exp Pharmacol. 2008;(182):313-33. doi: 10.1007/978-3-540-74806-9_15. Handb Exp Pharmacol. 2008. PMID: 18175098 Review.
Cited by
-
[Role of ketamine in sepsis and systemic inflammatory response syndrome].Anaesthesist. 2006 Aug;55(8):883-91. doi: 10.1007/s00101-006-1048-x. Anaesthesist. 2006. PMID: 16775727 Review. German.
-
A systematic review of the efficacy of ketamine for craniofacial pain.Can J Pain. 2023 Jun 26;7(1):2210167. doi: 10.1080/24740527.2023.2210167. eCollection 2023. Can J Pain. 2023. PMID: 37383673 Free PMC article. Review.
-
Neuron-Derived Extracellular Vesicles miRNA Profiles Identify Children Who Experience Adverse Events after Ketamine Administration for Procedural Sedation.Clin Pharmacol Ther. 2025 Jan;117(1):174-183. doi: 10.1002/cpt.3420. Epub 2024 Aug 20. Clin Pharmacol Ther. 2025. PMID: 39164873 Free PMC article.
-
Ketamine-From an Anesthetic to a Psychiatric Drug: Mechanisms of Action, Clinical Applications and Potential Risks.Molecules. 2025 Jun 30;30(13):2824. doi: 10.3390/molecules30132824. Molecules. 2025. PMID: 40649336 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical